Literature DB >> 12739738

Three-hour spontaneous GH secretion profile is as reliable as oral glucose tolerance test for the diagnosis of acromegaly.

S Grottoli1, P Razzore, D Gaia, M Gasperi, M Giusti, A Colao, E Ciccarelli, V Gasco, E Martino, E Ghigo, F Camanni.   

Abstract

The diagnosis of acromegaly, in an appropriate clinical context, usually relies on lack of GH suppression below 1 microg/l during OGTT coupled with elevated IGF-I levels. On the other hand, in normal subjects glucose-induced inhibition of GH secretory bursts without any further decrease of interpulse GH levels had already been shown. Based on the foregoing, we aimed to compare the diagnostic reliability of OGTT-induced GH nadir with that recorded during 3-h spontaneous GH secretion. In 59 acromegalic patients (17 male and 42 female, age, mean +/- SE 51.5 +/- 1.9, range 21-76 yr) and in 82 normal subjects (43 male and 39 female, age, mean +/- SE 35.7 +/- 1.5, range 15-72 yr) GH secretion was evaluated every 30 min from 0 to 180 min during slow saline infusion or OGTT (75 g at 0 min). A nadir GH concentration below 1 microg/l was recorded in all normal subjects either during OGTT or saline infusion if GH secretion was evaluated over 180 min. In contrast in acromegalic patients a nadir GH concentration below 1 microg/l never occurred in both conditions. This study shows that a 3-h spontaneous GH profile is as reliable as OGTT in the diagnosis of active acromegaly.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12739738     DOI: 10.1007/BF03345139

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  31 in total

Review 1.  Investigation protocol: acromegaly and its investigation.

Authors:  E Duncan; J A Wass
Journal:  Clin Endocrinol (Oxf)       Date:  1999-03       Impact factor: 3.478

Review 2.  Growth-hormone and prolactin excess.

Authors:  A Colao; G Lombardi
Journal:  Lancet       Date:  1998-10-31       Impact factor: 79.321

3.  Plasma insulin-like growth factor-I/somatomedin-C in acromegaly: correlation with the degree of growth hormone hypersecretion.

Authors:  A L Barkan; I Z Beitins; R P Kelch
Journal:  J Clin Endocrinol Metab       Date:  1988-07       Impact factor: 5.958

Review 4.  Nutritional regulation of the insulin-like growth factors.

Authors:  J P Thissen; J M Ketelslegers; L E Underwood
Journal:  Endocr Rev       Date:  1994-02       Impact factor: 19.871

5.  Glucose suppression of serum growth hormone in the diagnosis of acromegaly.

Authors:  J M Earll; L L Sparks; P H Forsham
Journal:  JAMA       Date:  1967-08-21       Impact factor: 56.272

Review 6.  Human growth hormone and human aging.

Authors:  E Corpas; S M Harman; M R Blackman
Journal:  Endocr Rev       Date:  1993-02       Impact factor: 19.871

Review 7.  Current treatment guidelines for acromegaly.

Authors:  S Melmed; I Jackson; D Kleinberg; A Klibanski
Journal:  J Clin Endocrinol Metab       Date:  1998-08       Impact factor: 5.958

8.  In obesity the somatotrope response to either growth hormone-releasing hormone or arginine is inhibited by somatostatin or pirenzepine but not by glucose.

Authors:  M Maccario; M Procopio; S Grottoli; S E Oleandri; P Razzore; F Camanni; E Ghigo
Journal:  J Clin Endocrinol Metab       Date:  1995-12       Impact factor: 5.958

9.  Paradoxical release of growth hormone during oral glucose tolerance test in patients with abnormal glucose tolerance.

Authors:  E O Grecu; R M Walter; E M Gold
Journal:  Metabolism       Date:  1983-02       Impact factor: 8.694

10.  Evaluation of disease status with sensitive measures of growth hormone secretion in 60 postoperative patients with acromegaly.

Authors:  P U Freda; K D Post; J S Powell; S L Wardlaw
Journal:  J Clin Endocrinol Metab       Date:  1998-11       Impact factor: 5.958

View more
  10 in total

1.  Acromegaly: are new tests needed?

Authors:  Anna Spada
Journal:  J Endocrinol Invest       Date:  2003-02       Impact factor: 4.256

2.  The R304X mutation of the aryl hydrocarbon receptor interacting protein gene in familial isolated pituitary adenomas: Mutational hot-spot or founder effect?

Authors:  G Occhi; M L Jaffrain-Rea; G Trivellin; N Albiger; F Ceccato; E De Menis; M Angelini; S Ferasin; A Beckers; F Mantero; C Scaroni
Journal:  J Endocrinol Invest       Date:  2010-03-30       Impact factor: 4.256

3.  Adrenal lesions in acromegaly: do metabolic aspects and aryl hydrocarbon receptor interacting protein gene have a role? Evaluation at baseline and after long-term follow-up.

Authors:  F Ceccato; G Occhi; N M Albiger; S Rizzati; S Ferasin; G Trivellin; F Mantero; C Scaroni
Journal:  J Endocrinol Invest       Date:  2010-07-01       Impact factor: 4.256

Review 4.  Biochemical investigations in diagnosis and follow up of acromegaly.

Authors:  Katharina Schilbach; Christian J Strasburger; Martin Bidlingmaier
Journal:  Pituitary       Date:  2017-02       Impact factor: 4.107

5.  Biochemical diagnosis and assessment of disease activity in acromegaly: a two-decade experience.

Authors:  Francesco M Minuto; Eugenia Resmini; Mara Boschetti; Alberto Rebora; Laura Fazzuoli; Marica Arvigo; Massimo Giusti; Diego Ferone
Journal:  Pituitary       Date:  2012-06       Impact factor: 4.107

Review 6.  Acromegaly in the elderly patients.

Authors:  Maria Rosaria Ambrosio; Irene Gagliardi; Sabrina Chiloiro; Ana Gonçalves Ferreira; Marta Bondanelli; Antonella Giampietro; Antonio Bianchi; Laura De Marinis; Maria Fleseriu; Maria Chiara Zatelli
Journal:  Endocrine       Date:  2020-02-14       Impact factor: 3.633

7.  Clinical aspects and therapeutic outcome in thyrotropin-secreting pituitary adenomas: a single center experience.

Authors:  E Macchia; M Gasperi; M Lombardi; L Morselli; A Pinchera; G Acerbi; G Rossi; E Martino
Journal:  J Endocrinol Invest       Date:  2009-10       Impact factor: 4.256

Review 8.  Dynamic tests for the diagnosis and assessment of treatment efficacy in acromegaly.

Authors:  Laure Cazabat; Jean-Claude Souberbielle; Philippe Chanson
Journal:  Pituitary       Date:  2008       Impact factor: 4.107

9.  Safety and specificity of the growth hormone suppression test in patients with diabetes.

Authors:  Pedro Weslley Rosario; Maria Regina Calsolari
Journal:  Endocrine       Date:  2014-05-17       Impact factor: 3.633

Review 10.  [The role of glucose and insulin in the metabolic regulation of growth hormone secretion].

Authors:  E L Sorkina; V V Chichkova; I A Sklyanik; M V Shestakova; G A Mel'nichenko; A Barkan
Journal:  Probl Endokrinol (Mosk)       Date:  2021-01-21
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.